Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-07-11

Clinical Trial Update: Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating adjunctive ganaxolone (GNX) versus placebo for tuberous sclerosis complex-related epilepsy has completed and results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ganaxolone (ganaxolone)

Snippet

Sponsor: Marinus Pharmaceuticals | Conditions: Tuberous Sclerosis Complex | Phase 3 | Status: COMPLETED | Results posted: 2025-07-11